These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37483530)

  • 1. Longitudinal associations between β-amyloid and cortical thickness in mild cognitive impairment.
    Mak E; Zhang L; Tan CH; Reilhac A; Shim HY; Wen MOQ; Wong ZX; Chong EJY; Xu X; Stephenson M; Venketasubramanian N; Zhou JH; O'Brien JT; Chen CL
    Brain Commun; 2023; 5(4):fcad192. PubMed ID: 37483530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
    d'Oleire Uquillas F; Jacobs HIL; Hanseeuw B; Marshall GA; Properzi M; Schultz AP; LaPoint MR; Johnson KA; Sperling RA; Vannini P
    Neuroimage Clin; 2018; 17():388-396. PubMed ID: 29159051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
    Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
    JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment.
    Stevens DA; Workman CI; Kuwabara H; Butters MA; Savonenko A; Nassery N; Gould N; Kraut M; Joo JH; Kilgore J; Kamath V; Holt DP; Dannals RF; Nandi A; Onyike CU; Smith GS
    Brain Commun; 2022; 4(1):fcac016. PubMed ID: 35233522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.
    Ye BS; Seo SW; Kim CH; Jeon S; Kim GH; Noh Y; Cho H; Yoon CW; Kim HJ; Jang EY; Lee J; Kim JH; Chin J; Lee JM; Kim JH; Seong JK; Kim CH; Choe YS; Lee KH; Na DL
    Neurobiol Aging; 2014 Feb; 35(2):291-300. PubMed ID: 24080178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
    Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer's Disease.
    Fan LY; Tzen KY; Chen YF; Chen TF; Lai YM; Yen RF; Huang YY; Shiue CY; Yang SY; Chiu MJ
    Front Aging Neurosci; 2018; 10():175. PubMed ID: 29967578
    [No Abstract]   [Full Text] [Related]  

  • 11. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults.
    Scott MR; Hampton OL; Buckley RF; Chhatwal JP; Hanseeuw BJ; Jacobs HI; Properzi MJ; Sanchez JS; Johnson KA; Sperling RA; Schultz AP
    Neuroimage; 2020 Oct; 220():116991. PubMed ID: 32512123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative impact of amyloid-β, lacunes, and downstream imaging markers on cognitive trajectories.
    Kim HJ; Yang JJ; Kwon H; Kim C; Lee JM; Chun P; Kim YJ; Jung NY; Chin J; Kim S; Woo SY; Choe YS; Lee KH; Kim ST; Kim JS; Lee JH; Weiner MW; Na DL; Seo SW
    Brain; 2016 Sep; 139(Pt 9):2516-27. PubMed ID: 27329772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.
    Tosun D; Schuff N; Mathis CA; Jagust W; Weiner MW;
    Brain; 2011 Apr; 134(Pt 4):1077-88. PubMed ID: 21429865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma adiponectin levels predict cognitive decline and cortical thinning in mild cognitive impairment with beta-amyloid pathology.
    Kim KY; Ha J; Kim M; Cho SY; Kim H; Kim E;
    Alzheimers Res Ther; 2022 Nov; 14(1):165. PubMed ID: 36329496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults.
    Rodriguez-Vieitez E; Montal V; Sepulcre J; Lois C; Hanseeuw B; Vilaplana E; Schultz AP; Properzi MJ; Scott MR; Amariglio R; Papp KV; Marshall GA; Fortea J; Johnson KA; Sperling RA; Vannini P
    Mol Psychiatry; 2021 Dec; 26(12):7813-7822. PubMed ID: 34588623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
    Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
    Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Fan Z; Brooks DJ; Okello A; Edison P
    Brain; 2017 Mar; 140(3):792-803. PubMed ID: 28122877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.